Ozagrel is primarily used as an antiplatelet agent, helping to prevent the formation of blood clots. It works by inhibiting thromboxane A2 synthase, an enzyme involved in platelet aggregation and vasoconstriction. This action makes it useful in the treatment of ischemic stroke, where maintaining blood flow to the brain is critical. By selectively blocking this pathway, Ozagrel helps reduce the risk of recurrent cerebral ischemia without significantly affecting prostacyclin levels, which supports vascular health. It is often administered intravenously in acute settings and has been studied for its potential neuroprotective effects due to improved microcirculation in brain tissue. Its application is mainly in acute stroke management, particularly in countries where it is approved for clinical use.